Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Lesson Of Jevtana: With A Survival Advantage, All Things Are Possible

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

The expedited review and approval of Sanofi-Aventis’ oncologic Jevtana (cabazitaxel) shows the power of a clearly demonstrated survival advantage to overcome regulatory hurdles.
Advertisement

Related Content

Case Studies In FDA's Regulatory Interpretation Of Clinical Trials
Why Survival Is The Fittest Endpoint For HRPC: The Problem With Pain
Why Survival Is The Fittest Endpoint For HRPC: The Problem With Pain
Jevtana Clinical Development
Egrifta Approval: FDA Balanced Modest Efficacy, Off-Label Use Potential With Unmet Medical Need
Out Of The Shadow Of REMS: FDA Review Documents Show Emerging Importance Of Post-Marketing Requirements
Prostate Cancer Market Snapshot: More Than Provenge
Score One For FDAAA: Uloric Approval Was Clinched By Post-Market Powers
With Jevtana Approved For Advanced Prostate Cancer, Sanofi Could See Expansion To First-Line Use
GPC Biotech’s Satraplatin Fails To Meet Survival Endpoint In SPARC Trial

Topics

Advertisement
UsernamePublicRestriction

Register

PS004700

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel